Xenotransplantation of acellular adipose matrix (AAM) has come to prominence as an intriguing option for soft tissue reconstruction. However, the presence of immunogenic antigens within AAM can trigger unfavorable immune reactions, leading to inadequate in vivo regeneration outcomes. Therefore, the development of advanced technology capable of modulating immune responses is crucial for the therapeutic implementation of AAM xenografts. In this work, an innovative technique is created to bypass the immune system by covering the surface of both AAM and Arg-Gly-Asp (RGD) peptide-modified AAM xenografts with autologous red blood cell (RBC) membrane. The RBC membrane coating remained persistent and exhibited no significant decline even after 21 days. Moreover, it effectively reduced the expression of antigen major histocompatibility complex class 1 (MHC1) on the AAM surface. Following xenogeneic transplantation, the RBC-coated xenografts demonstrated increased expression of the adipogenic factor PPAR-γ, Adipoq, Fabp4, Fasn, and Plin1 and higher numbers of adipocytes. In addition, they exhibited decreased expression of immunological factors, including IL-6,IL-2, IFN-γ, and TNF-α, and fewer inflammatory cells. These findings indicate that RBC membrane coating successfully suppressed immune responses and promoted increased adipogenesis in AAM xenografts. Therefore, AAM camouflage coating with RBC has a lot of potential as a biomaterial for soft tissue reconstruction in clinical settings.
Impact Statement
In this study, we present a natural and easily accessible red blood cell membrane nanoparticles-RGD peptide-acellular adipose matrix (AAM) platform. This platform remained stable for over 3 weeks, blocked MHC1 antibody, suppressed immune responses, and promoted increased adipogenesis in xenotransplantation. The findings of this study open up new possibilities for in situ regenerative repair of soft tissue defects.
Get full access to this article
View all access options for this article.
References
1.
MorrisAH, StamerDK, KyriakidesTR. The host response to naturally-derived extracellular matrix biomaterials. Semin Immunol, 2017; 29:72–91; doi: 10.1016/j.smim.2017.01.002
2.
BaldwinP, LiDJ, AustonDA, et al.Autograft, allograft, and bone graft substitutes: Clinical evidence and indications for use in the setting of orthopaedic trauma surgery. J Orthop Trauma, 2019; 33(4):203–213; doi: 10.1097/BOT.0000000000001420
3.
YangJ, ZhouC, FuJ, et al.In situ adipogenesis in biomaterials without cell seeds: Current status and perspectives. Front Cell Dev Biol, 2021; 9:647149; doi: 10.3389/fcell.2021.647149
4.
WagnerT, HummelinkS, UlrichD. Past, present and future in plastic flap surgery: From surgeon to bioengineer driven progress. A personal view. J Tissue Viability, 2022; 31(4):800–803; doi: 10.1016/j.jtv.2022.06.007
5.
KouniavskiE, EgoziD, WolfY. Techniques and Innovations in Flap Engineering: A Review. Plast Reconstr Surg Glob Open, 2022; 10(9):e4523; doi: 10.1097/GOX.0000000000004523
6.
MajorGS, SimcockJW, WoodfieldTBF, et al.Overcoming functional challenges in autologous and engineered fat grafting trends. Trends Biotechnol, 2022; 40(1):77–92; doi: 10.1016/j.tibtech.2021.04.006
7.
PeirsmanA, NguyenHT, Van WaeyenbergeM, et al.Vascularized adipose tissue engineering: Moving towards soft tissue reconstruction. Biofabrication, 2023; 15(3); doi: 10.1088/1758-5090/acd7a5
8.
SanoH, OrbayH, TerashiH, et al.Acellular adipose matrix as a natural scaffold for tissue engineering. J Plast Reconstr Aesthet Surg, 2014; 67(1):99–106; doi: 10.1016/j.bjps.2013.08.006
9.
NguyenMTN, TranHLB. Fabrication of an injectable acellular adipose matrix for soft tissue regeneration. J Sci Adv Mater Devices, 2021; 6(1):1–10; doi: 10.1016/j.jsamd.2020.10.002
10.
GiatsidisG, SuccarJ, WatersTD, et al.Tissue-engineered soft-tissue reconstruction using noninvasive mechanical preconditioning and a shelf-ready allograft adipose matrix. Plast Reconstr Surg, 2019; 144(4):884–895; doi: 10.1097/PRS.0000000000006085
11.
ChenK, XuM, LuF, et al.Development of matrix metalloproteinases-mediated extracellular matrix remodeling in regenerative medicine: A mini review. Tissue Eng Regen Med, 2023; 20(5):661–670; doi: 10.1007/s13770-023-00536-x
12.
XuM, SuT, JinX, et al.Inflammation-mediated matrix remodeling of extracellular matrix-mimicking biomaterials in tissue engineering and regenerative medicine. Acta Biomater, 2022; 151:106–117; doi: 10.1016/j.actbio.2022.08.015
13.
HuleihelL, HusseyGS, NaranjoJD, et al.Matrix-bound nanovesicles within ECM bioscaffolds. Sci Adv, 2016; 2(6):e1600502; doi: 10.1126/sciadv.1600502
14.
KaweckiM, ŁabuśW, Klama-BarylaA, et al.A review of decellurization methods caused by an urgent need for quality control of cell-free extracellular matrix’ scaffolds and their role in regenerative medicine. J Biomed Mater Res B Appl Biomater, 2018; 106(2):909–923; doi: 10.1002/jbm.b.33865
15.
NeishabouriA, Soltani KhaboushanA, DaghighF, et al.Decellularization in tissue engineering and regenerative medicine: Evaluation, modification, and application methods. Front Bioeng Biotechnol, 2022; 10:805299; doi: 10.3389/fbioe.2022.805299
LuT, YangB, WangR, et al.Xenotransplantation: Current status in preclinical research. Front Immunol, 2019; 10:3060; doi: 10.3389/fimmu.2019.03060
18.
Capella-MonsonísH, ZeugolisDI. Decellularized xenografts in regenerative medicine: From processing to clinical application. Xenotransplantation, 2021; 28(4):e12683; doi: 10.1111/xen.12683
19.
HeY, LinM, WangX, et al.Optimized adipose tissue engineering strategy based on a neo-mechanical processing method. Wound Repair Regen, 2018; 26(2):163–171; doi: 10.1111/wrr.12640
20.
HeY, XiaJ, ChenH, et al.Human adipose liquid extract induces angiogenesis and adipogenesis: A novel cell-free therapeutic agent. Stem Cell Res Ther, 2019; 10(1):252; doi: 10.1186/s13287-019-1356-0
21.
AllmanAJ, McPhersonTB, BadylakSF, et al.Xenogeneic extracellular matrix grafts elicit a TH2-restricted immune response. Transplantation, 2001; 71(11):1631–1640; doi: 10.1097/00007890-200106150-00024
22.
GaliliU. Chapter 10—Human anti-gal and anti-non-gal immune response to porcine tissue implants. In: Host Response to Biomaterials. (BadylakSF. ed.) Academic Press: Oxford; 2015; pp. 239–267; doi: 10.1016/B978-0-12-800196-7.00010-4
23.
ZhouQ, LiT, WangK, et al.Current status of xenotransplantation research and the strategies for preventing xenograft rejection. Front Immunol, 2022; 13:928173; doi: 10.3389/fimmu.2022.928173
24.
MaedaA, KogataS, ToyamaC, et al.The innate cellular immune response in xenotransplantation. Front Immunol, 2022; 13:858604; doi: 10.3389/fimmu.2022.858604
25.
LuT-Y, XuX-L, DuX-G, et al.Advances in innate immunity to overcome immune rejection during xenotransplantation. Cells, 2022; 11(23):3865; doi: 10.3390/cells11233865
26.
GoerlichCE, SinghAK, GriffithBP, et al.The immunobiology and clinical use of genetically engineered porcine hearts for cardiac xenotransplantation. Nat Cardiovasc Res, 2022; 1(8):715–726; doi: 10.1038/s44161-022-00112-x
27.
LeiT, ChenL, WangK, et al.Genetic engineering of pigs for xenotransplantation to overcome immune rejection and physiological incompatibilities: The first clinical steps. Front Immunol, 2022; 13:1031185.
28.
Di StefanoDA, ZaniolT, CinciL, et al.Chemical, clinical and histomorphometric comparison between equine bone manufactured through enzymatic antigen-elimination and bovine bone made non-antigenic using a high-temperature process in post-extractive socket grafting. A Comparative Retrospective Clinical Study. Dent J (Basel), 2019; 7(3):70; doi: 10.3390/dj7030070
29.
FindeisenK, MorticelliL, GoeckeT, et al.Toward acellular xenogeneic heart valve prostheses: Histological and biomechanical characterization of decellularized and enzymatically deglycosylated porcine pulmonary heart valve matrices. Xenotransplantation, 2020; 27(5):e12617; doi: 10.1111/xen.12617
30.
WigginsSC, AbuidNJ, Gattás-AsfuraKM, et al.Nanotechnology approaches to modulate immune responses to cell-based therapies for Type 1 diabetes. J Diabetes Sci Technol, 2020; 14(2):212–225; doi: 10.1177/1932296819871947
HuC-MJ, ZhangL, AryalS, et al.Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc Natl Acad Sci U S A, 2011; 108(27):10980–10985; doi: 10.1073/pnas.1106634108
33.
FengS, LiH, RenY, et al.RBC membrane camouflaged boron nitride nanospheres for enhanced biocompatible performance. Colloids Surf B Biointerfaces, 2020; 190:110964; doi: 10.1016/j.colsurfb.2020.110964
34.
LiuH, SuY-Y, JiangX-C, et al.Cell membrane-coated nanoparticles: A novel multifunctional biomimetic drug delivery system. Drug Deliv Transl Res, 2023; 13(3):716–737; doi: 10.1007/s13346-022-01252-0
35.
BianconiE, PiovesanA, FacchinF, et al.An estimation of the number of cells in the human body. Ann Hum Biol, 2013; 40(6):463–471; doi: 10.3109/03014460.2013.807878
36.
Culp-HillR, ZhengC, ReiszJA, et al.Red blood cell metabolism in down syndrome: Hints on metabolic derangements in aging. Blood Adv, 2017; 1(27):2776–2780; doi: 10.1182/bloodadvances.2017011957
37.
XueL, LaiJ, WangS, et al.Single-shot slightly-off-axis interferometry based Hilbert phase microscopy of red blood cells. Biomed Opt Express, 2011; 2(4):987–995; doi: 10.1364/BOE.2.000987
38.
PierigèF, SerafiniS, RossiL, et al.Cell-based drug delivery. Adv Drug Deliv Rev, 2008; 60(2):286–295; doi: 10.1016/j.addr.2007.08.029
39.
BoettcherAN, CunnickJE, PowellEJ, et al.Porcine signal regulatory protein alpha binds to human CD47 to inhibit phagocytosis: Implications for human hematopoietic stem cell transplantation into severe combined immunodeficient pigs. Xenotransplantation, 2019; 26(2):e12466; doi: 10.1111/xen.12466
40.
RodriguezPL, HaradaT, ChristianDA, et al.Minimal “Self” peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. Science, 2013; 339(6122):971–975; doi: 10.1126/science.1229568
41.
HoCCM, GuoN, SockoloskyJT, et al.“Velcro” engineering of high affinity CD47 ectodomain as signal regulatory protein α (SIRPα) antagonists that enhance antibody-dependent cellular phagocytosis. J Biol Chem, 2015; 290(20):12650–12663; doi: 10.1074/jbc.M115.648220
42.
HanX, WangC, LiuZ. Red blood cells as smart delivery systems. Bioconjug Chem, 2018; 29(4):852–860; doi: 10.1021/acs.bioconjchem.7b00758
43.
FangRH, HuC-MJ, ZhangL. Nanoparticles disguised as red blood cells to evade the immune system. Expert Opin Biol Ther, 2012; 12(4):385–389; doi: 10.1517/14712598.2012.661710
44.
KimDD, MiwaT, KimuraY, et al.Deficiency of decay-accelerating factor and complement receptor 1-related gene/protein y on murine platelets leads to complement-dependent clearance by the macrophage phagocytic receptor CRIg. Blood, 2008; 112(4):1109–1119; doi: 10.1182/blood-2008-01-134304
45.
BarclayAN, Van Den BergTK. The interaction between signal regulatory protein alpha (SIRPα) and CD47: Structure, function, and therapeutic target. Annu Rev Immunol, 2014; 32:25–50; doi: 10.1146/annurev-immunol-032713-120142
46.
OldenborgP-A, ZheleznyakA, FangY-F, et al.Role of CD47 as a marker of self on red blood cells. Science, 2000; 288(5473):2051–2054; doi: 10.1126/science.288.5473.2051
47.
KrollAV, FangRH, ZhangL. Biointerfacing and applications of cell membrane-coated nanoparticles. Bioconjug Chem, 2017; 28(1):23–32; doi: 10.1021/acs.bioconjchem.6b00569
48.
WibroePP, AnselmoAC, NilssonPH, et al.Bypassing adverse injection reactions to nanoparticles through shape modification and attachment to erythrocytes. Nat Nanotechnol, 2017; 12(6):589–594; doi: 10.1038/nnano.2017.47
49.
WangB, YangP, DingY, et al.Improvement of the biocompatibility and potential stability of chronically implanted electrodes incorporating coating cell membranes. ACS Appl Mater Interfaces, 2019; 11(9):8807–8817; doi: 10.1021/acsami.8b20542
50.
FanZ, LiPY, DengJ, et al.Cell membrane coating for reducing nanoparticle-induced inflammatory responses to scaffold constructs. Nano Res, 2018; 11(10):5573–5583; doi: 10.1007/s12274-018-2084-y
51.
NishiguchiA, TaguchiT. Development of an immunosuppressive camouflage-coating platform with nanocellulose and cell membrane vesicles. J Biomater Sci Polym Ed, 2020; 31(15):1912–1924; doi: 10.1080/09205063.2020.1783060
52.
LiuK, HeY, YaoY, et al.Methoxy polyethylene glycol modification promotes adipogenesis by inducing the production of regulatory T cells in xenogeneic acellular adipose matrix. Mater Today Bio, 2021; 21:100705; doi: 10.1016/j.mtbio.2021.100161
53.
TaoC, NieX, ZhuW, et al.Autologous cell membrane coatings on tissue engineering xenografts for suppression and alleviation of acute host immune responses. Biomaterials, 2020; 258:120310; doi: 10.1016/j.biomaterials.2020.120310
54.
SchusslerO, CoiraultC, Louis-TisserandM, et al.Use of arginine-glycine-aspartic acid adhesion peptides coupled with a new collagen scaffold to engineer a myocardium-like tissue graft. Nat Clin Pract Cardiovasc Med, 2009; 6(3):240–249; doi: 10.1038/ncpcardio1451
55.
HuangJ, LaiW, WangQ, et al.Effective triple-negative breast cancer targeted treatment using iRGD-modified RBC membrane-camouflaged nanoparticles. Int J Nanomedicine, 2021; 16:7497–7515; doi: 10.2147/IJN.S321071
56.
HosnyG, IsmailW, MakboulR, et al.Increased glomerular Bax/Bcl2 ratio is positively correlated with glomerular sclerosis in lupus nephritis. Pathophysiology, 2018; 25(2):83–88; doi: 10.1016/j.pathophys.2018.01.003
57.
YuC, KornmullerA, BrownC, et al.Decellularized adipose tissue microcarriers as a dynamic culture platform for human adipose-derived stem/stromal cell expansion. Biomaterials, 2017; 120:66–80; doi: 10.1016/j.biomaterials.2016.12.017
58.
YeaJ-H, BaeTS, KimBJ, et al.Regeneration of the rotator cuff tendon-to-bone interface using umbilical cord-derived mesenchymal stem cells and gradient extracellular matrix scaffolds from adipose tissue in a rat model. Acta Biomater, 2020; 114:104–116; doi: 10.1016/j.actbio.2020.07.020
59.
ChunSY, LimJO, LeeEH, et al.Preparation and characterization of human adipose tissue-derived extracellular matrix, growth factors, and stem cells: A concise review. Tissue Eng Regen Med, 2019; 16(4):385–393; doi: 10.1007/s13770-019-00199-7
60.
GiatsidisG, SuccarJ, HaddadA, et al.Preclinical optimization of a shelf-ready, injectable, human-derived, decellularized allograft adipose matrix. Tissue Eng Part A, 2019; 25(3-4):271–287; doi: 10.1089/ten.TEA.2018.0052
61.
KokaiLE, SchillingBK, ChnariE, et al.Injectable allograft adipose matrix supports adipogenic tissue remodeling in the nude mouse and human. Plast Reconstr Surg, 2019; 143(2):299e–309e; doi: 10.1097/PRS.0000000000005269
62.
CrumRJ, Capella-MonsonísH, ChangJ, et al.Biocompatibility and biodistribution of matrix-bound nanovesicles in vitro and in vivo. Acta Biomater, 2023; 155:113–122; doi: 10.1016/j.actbio.2022.11.026
63.
TanQ-W, ZhangY, LuoJ-C, et al.Hydrogel derived from decellularized porcine adipose tissue as a promising biomaterial for soft tissue augmentation. J Biomed Mater Res A, 2017; 105(6):1756–1764; doi: 10.1002/jbm.a.36025
64.
CicuéndezM, CasarrubiosL, FeitoMJ, et al.Effects of human and porcine adipose extracellular matrices decellularized by enzymatic or chemical methods on macrophage polarization and immunocompetence. Int J Mol Sci, 2021; 22(8):3847; doi: 10.3390/ijms22083847
65.
WongML, WongJL, VapniarskyN, et al.In vivo xenogeneic scaffold fate is determined by residual antigenicity and extracellular matrix preservation. Biomaterials, 2016; 92:1–12; doi: 10.1016/j.biomaterials.2016.03.024
66.
KasraviM, AhmadiA, BabajaniA, et al.Immunogenicity of decellularized extracellular matrix scaffolds: A bottleneck in tissue engineering and regenerative medicine. Biomater Res, 2023; 27(1):10; doi: 10.1186/s40824-023-00348-z
67.
GuoG, JinL, WuB, et al.A method for simultaneously crosslinking and functionalizing extracellular matrix-based biomaterials as bioprosthetic heart valves with enhanced endothelialization and reduced inflammation. Acta Biomater, 2021; 119:89–100; doi: 10.1016/j.actbio.2020.10.029
68.
GrebenikEA, GafarovaER, IstranovLP, et al.Mammalian pericardium-based bioprosthetic materials in xenotransplantation and tissue engineering. Biotechnol J, 2020; 15(8):e1900334; doi: 10.1002/biot.201900334
69.
CissellDD, HuJC, GriffithsLG, et al.Antigen removal for the production of biomechanically functional, xenogeneic tissue grafts. J Biomech, 2014; 47(9):1987–1996; doi: 10.1016/j.jbiomech.2013.10.041
70.
DaugsA, LehmannN, ErogluD, et al.In vitro detection system to evaluate the immunogenic potential of xenografts. Tissue Eng Part C Methods, 2018; 24(5):280–288; doi: 10.1089/ten.TEC.2017.0532
71.
KrishnakumarGS, SampathS, MuthusamyS, et al.Importance of crosslinking strategies in designing smart biomaterials for bone tissue engineering: A systematic review. Mater Sci Eng C Mater Biol Appl, 2019; 96:941–954; doi: 10.1016/j.msec.2018.11.081
72.
BhattacharjeeP, AhearneM. Significance of crosslinking approaches in the development of next generation hydrogels for corneal tissue engineering. Pharmaceutics, 2021; 13(3):319; doi: 10.3390/pharmaceutics13030319
ZhengB-D, XiaoM. Red blood cell membrane nanoparticles for tumor phototherapy. Colloids Surf B Biointerfaces, 2022; 220:112895; doi: 10.1016/j.colsurfb.2022.112895
75.
IshidaT, MaedaR, IchiharaM, et al.Accelerated clearance of PEGylated liposomes in rats after repeated injections. J Control Release, 2003; 88(1):35–42; doi: 10.1016/S0168-3659(02)00462-5
76.
ArmstrongJK, HempelG, KolingS, et al.Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer, 2007; 110(1):103–111; doi: 10.1002/cncr.22739
77.
RenH, LiuJ, LiY, et al.Oxygen self-enriched nanoparticles functionalized with erythrocyte membranes for long circulation and enhanced phototherapy. Acta Biomater, 2017; 59:269–282; doi: 10.1016/j.actbio.2017.06.035
78.
RaoL, BuL-L, XuJ-H, et al.Red Blood Cell Membrane as a Biomimetic Nanocoating for Prolonged Circulation Time and Reduced Accelerated Blood Clearance. Small, 2015; 11(46):6225–6236; doi: 10.1002/smll.201502388
79.
GarayRP, El-GewelyR, ArmstrongJK, et al.Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. Expert Opin Drug Deliv, 2012; 9(11):1319–1323; doi: 10.1517/17425247.2012.720969
80.
ZhangP, SunF, LiuS, et al.Anti-PEG antibodies in the clinic: Current issues and beyond PEGylation. J Control Release, 2016; 244(Pt B):184–193; doi: 10.1016/j.jconrel.2016.06.040
81.
KhanMA. T regulatory cell mediated immunotherapy for solid organ transplantation: A clinical perspective. Mol Med, 2017; 22:892–904; doi: 10.2119/molmed.2016.00050
82.
VicencioJM, GalluzziL, TajeddineN, et al.Senescence, apoptosis or autophagy? When a damaged cell must decide its path–a mini-review. Gerontology, 2008; 54(2):92–99; doi: 10.1159/000129697
83.
KaminskyyVO, ZhivotovskyB. Free radicals in cross talk between autophagy and apoptosis. Antioxid Redox Signal, 2014; 21(1):86–102; doi: 10.1089/ars.2013.5746
84.
DavisS, HockingS, WattMJ, et al.Metabolic effects of lipectomy and of adipose tissue transplantation. Obesity (Silver Spring), 2023; 31(1):7–19; doi: 10.1002/oby.23601
85.
TranTT, KahnCR. Transplantation of adipose tissue and stem cells: Role in metabolism and disease. Nat Rev Endocrinol, 2010; 6(4):195–213; doi: 10.1038/nrendo.2010.20
86.
TsiloulisT, RaajendiranA, KeenanSN, et al.Impact of human visceral and glutealfemoral adipose tissue transplant on glycemic control in a mouse model of diet-induced obesity. Am J Physiol Endocrinol Metab, 2020; 319(3):E519–E528; doi: 10.1152/ajpendo.00373.2019
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
